Immunotherapy for Infectious Diseases

234 Kilby and Bucy
64. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency
virus infection. N Engl J Med 1993; 328:327–335.
65. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent
courses of interleukin-2 in patients with human immunodeficiency virus infection. A
preliminary study. N Engl J Med 1995; 332:567–575.
66. O’Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1
replication can be increased in peripheral blood of seropositive patients after influenza
vaccination. Blood 1995; 86:1082–1089.
67. Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma
human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal
vaccine. J Infect Dis 1996; 174:1191–1199.
68. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common
recall antigen on viral expression in patients infected with human immunodeficiency virus
type 1. N Engl J Med 1996; 334:1222–1230.
69. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in virus load
markers during AIDS-associated opportunistic diseases in HIV-infected persons. J Infect
Dis 1996; 174:401–403.
70. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, Quinn TC. The effect
of acute infectious diseases on plasma HIV-1 viral load and the expression of serologic
markers of immune activation among HIV-infected adults. J Infect Dis 1998;
178:1642–1648.
71. Dezube BJ, Lederman MM, Spritzler JG, et al. High-dose pentoxifylline in patients with
AIDS: inhibition of tumor necrosis factor production. J Infect Dis 1995; 171:1628–1632.
72. Landman D, Sarai A, Sathe SS. Use of pentoxifylline therapy for patients with AIDSrelated
wasting: pilot study. Clin Infect Dis 1994; 18:97–99.
73. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on
HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical
trial. AIDS 1996; 10:1501–1507.
74. Kilby JM, Tabereaux PB, Mulanovich V, Shaw GM, Bucy RP, Saag MS. Effects of tapering
doses of oral prednisone on viral load among HIV-infected patients with unexplained
weight loss. AIDS Res Hum Retroviruses 1997; 13:1533–1537.
75. Andrieu JM, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic
human immunodeficiency virus type 1-seropositive patients treated with prednisolone for
1 year. J Infect Dis 1995; 171:523–530.
76. Pakker NG, Notermans DW, deBoer RJ, et al. Biphasic kinetics of peripheral blood T cells
after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.
Nat Med 1998; 2:208–214.
77. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(�) lymphocytes
after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest
1999; 103:1391–1398.
78. Dieli F, Friscia G, Di Sano C, et al. Sequestration of T lymphocytes to body fluids in
tuberculosis: reversal of anergy following chemotherapy. J Infect Dis 1999;
180:225–228.
79. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4� T-lymphocyte
regeneration after intensive chemotherapy. N Engl J Med 1995; 332:143–149.
80. Moreland LW, Bucy RP, Koopman WJ. Regeneration of T cells after chemotherapy.
N Engl J Med 1995; 332:1651–1652.
81. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on
CD4� T cell homeostasis and function in advanced HIV disease. Science 1997;
277:112–116.